查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1529664

血漿蛋白酶 C1 抑制劑市場規模、佔有率和趨勢分析報告：按藥物類別、劑型、分銷管道、地區和細分市場預測，2024-2030 年

Plasma Protease C1-inhibitor Market Size, Share & Trends Analysis Report By Drug Class (C1-inhibitors, Kallikrein Inhibitor), By Dosage Form (Lyphophlised, Injectables), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

血漿蛋白酶 C1 抑制劑市場成長與趨勢：

根據Grand View Research, Inc. Masu的最新報告，預計2030年全球血漿蛋白酶C1抑制劑市場規模將達到62.1億美元，2024年至2030年複合年成長率為9.79%。

血漿蛋白酶 C1 抑制劑的全球市場是由遺傳性血管水腫 (HAE)（一種罕見的遺傳疾病）發病率上升以及對 C1 抑制劑等有效治療方法的需求不斷成長所推動的。此外，生物技術的進步提高了生產效率，並使這些療法更容易獲得。

對 HAE 及相關疾病的認知提高和診斷改進進一步促進了市場的顯著成長。 HAE 影響著全世界約五萬分之一的人，這凸顯了迫切需要治療方法來緩解症狀並改善患者的生活品質。此外，生物技術的進步促進了基因工程產品的開發，為世界各地的患者帶來了更大的功效和可及性。這些促進因素對於塑造 C1-INH 產業格局、推動新治療方案的採用和增加投資至關重要。

治療技術的創新將重新定義各種病症的治療標準。例如，採用長效製劑可延長治療效果、減少治療頻率、提高患者遵從性。此外，正在進行的針對 HAE 以外的新興適應症（例如抗體介導的自體免疫疾病）的研究表明，治療方法在解決未滿足的醫療需求方面具有多功能性和潛力。這些進步突顯了該行業的動態本質，這是由旨在擴大治療應用和最佳化患者治療結果的持續研發努力所推動的。

隨著產業不斷擴張，市場相關人員越來越注重解決關鍵挑戰和抓住成長機會。監管發展和有利的報銷政策預計將進一步推動市場擴張，並使全球患者更容易獲得 C1-INH 治療。市場開拓公司正在利用這些監管發展來簡化產業進入流程並確保及時獲得創新治療方法。 CSL Behring 和工業)等公司正在積極投資於產能擴張，以滿足不斷成長的需求並確保全球供應鏈的彈性。此外，我們與研究機構和監管機構的合作促進了創新並加快了新 C1-INH 治療的核准流程。這些積極主動的舉措強調了我們對增加治療選擇和加強市場領導地位的承諾，並使我們的相關人員能夠在不斷發展的醫療保健領域實現持續成長和成功。

血漿蛋白酶 C1 抑制劑市場報告亮點

  • 從藥物類別來看，C1抑制劑將在2023年佔據市場主導地位並佔據最大佔有率。由於主要企業實施研發舉措，選擇性緩激肽 B2 受體拮抗劑預計在預測期內將以最快的成長率成長。
  • 從劑型來看，冷凍乾燥製劑由於穩定性、保存期限長、易於儲存和運輸而成為血漿蛋白酶 C1 抑制劑治療的首選，將在 2023 年佔據市場佔有率，從而增加對患者和醫療保健提供者的需求。保證雙方的便利。
  • 從分銷管道來看，2023年醫院藥局將佔據市場主導地位。這是因為醫院藥局隨處可見，符合法規，並且能夠有效處理血漿蛋白酶 C1 抑制劑等專門療法。
  • 由於高額醫療保健支出、先進的醫療保健基礎設施、強大的研究以及針對遺傳性血管性水腫等各種罕見疾病的血漿蛋白酶C1 抑製劑治療的大量採用，北美在市場中佔據主導地位，預計到2023 年將成為最大的市場。

目錄

第1章調查方法和範圍

第2章執行概述

第3章血漿蛋白酶 C1 抑制劑市場變數、趨勢與範圍

  • 血漿蛋白酶C1抑制劑市場系統展望
    • 母市場展望
    • 助劑市場前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 血漿蛋白酶 C1 抑制劑市場分析工具
    • 波特五力分析
    • PESTLE分析

第 4 章 2018-2030 年血漿蛋白酶 C1 抑制劑市場分析（按藥物類別）（百萬美元）

  • 2023 年和 2030 年按藥物類別分類的市場佔有率佔有率
  • 細分儀表板
  • 血漿蛋白酶 C1 抑制劑市場 – 依藥物類別分類的前景
    • C1抑制劑
    • 激肽釋放酶抑制劑
    • 選擇性緩激肽 B2 受體拮抗劑

第 5 章 2018-2030 年血漿蛋白酶 C1 抑制劑市場分析（以劑型）（百萬美元）

  • 2023 年和 2030 年按劑型分類的市場佔有率佔有率
  • 細分儀表板
  • 血漿蛋白酶 C1 抑制劑市場 – 以劑型分類的展望
    • 冷凍乾燥
    • 注射

第 6 章 2018-2030 年血漿蛋白酶 C1 抑制劑市場分析（按分銷管道）（百萬美元）

  • 2023 年和 2030 年按分銷管道分類的市場佔有率佔有率
  • 細分儀表板
  • 血漿蛋白酶 C1 抑制劑市場 – 按分銷管道分類的展望
    • 醫院藥房
    • 零售藥房
    • 網路藥房

第 7 章血漿蛋白酶 C1 抑制劑市場：按藥物類別分類的區域估計和趨勢分析

  • 血漿蛋白酶 C1 抑制劑市場：區域展望
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第8章 競爭格局

  • 市場參與企業分類
  • 主要企業簡介
    • CSL
    • Takeda Pharmaceutical Company Limited
    • Pharming
    • KalVista Pharmaceuticals.
    • Sanquin
    • BioCryst Pharmaceuticals, Inc.
    • CENTOGENE NV
Product Code: GVR-4-68040-328-1

Plasma Protease C1-inhibitor Market Growth & Trends:

The global plasma protease C1-inhibitor market size is anticipated to reach USD 6.21 billion by 2030, expanding at a CAGR of 9.79% from 2024 to 2030, according to a new report by Grand View Research, Inc. The global market for plasma protease C1-inhibitor is propelled by multiple pivotal factors such as the rising incidence of hereditary angioedema (HAE), a rare genetic disorder, increases the demand for effective therapies such as C1-inhibitor. Furthermore, advancements in biotechnology improve production efficiency, making these therapies more accessible.

Increased awareness and improved diagnosis of HAE and related conditions further contribute to substantial market growth. HAE affects approximately 1 in 50,000 individuals worldwide, underscoring the urgent need for therapies to alleviate symptoms and improve patient quality of life. Furthermore, advancements in biotechnology have enabled the development of recombinant products, which promise enhanced efficacy and accessibility for patients globally. These drivers are pivotal in shaping the landscape of the C1-INH industry, facilitating greater adoption and investment in novel treatment options.

Innovations in therapies are set to redefine treatment standards across various conditions. For instance, the introduction of long-acting formulations offers extended therapeutic effects, reducing treatment frequency and improving patient compliance. Additionally, ongoing research into new indications beyond HAE, such as antibody-mediated autoimmune diseases, showcases the versatility and potential of therapies in addressing unmet medical needs. These advancements underscore the dynamic nature of the industry, driven by continuous research and development efforts aimed at expanding therapeutic applications and optimizing patient outcomes.

Industry continues to expand; market players are increasingly focused on addressing key challenges and seizing opportunities for growth. Regulatory advancements and favorable reimbursement policies are anticipated to further propel market expansion, facilitating greater accessibility to C1-INH therapies for patients globally. Market players are leveraging these regulatory developments to streamline industry entry processes and ensure timely access to innovative treatments. Companies such as CSL Behring and Takeda Pharmaceutical are actively investing in expanding production capacities to meet escalating demand and ensure global supply chain resilience. Moreover, partnerships with research institutions and regulatory bodies are fostering innovation and accelerating the approval process for new C1-INH therapies. These proactive measures underscore a commitment to advancing treatment options and reinforcing market leadership, positioning stakeholders for sustained growth and success in the evolving healthcare landscape.

Plasma Protease C1-inhibitor Market Report Highlights:

  • Based on drug class, C1-inhibitors dominated the market and accounted for the largest share in 2023. Selective bradykinin B2 receptor antagonist anticipated to grow at the fastest growth rate over the forecast period owing to undergoing R&D initiatives being undertaken by major players
  • Based on dosage form, the lyophilized segment held a dominant share in 2023 due to their stability, longer shelf life, and ease of storage and transportation, making them preferred for plasma protease C1-inhibitor therapies, ensuring efficacy and convenience for patients and healthcare providers alike
  • Based on distribution channel, hospital pharmacies dominated the market in 2023 due to their widespread accessibility, regulatory compliance, and ability to handle specialized therapies like plasma protease C1-inhibitor effectively
  • North America dominated the market and accounted for the largest share in 2023 owing to high healthcare spending, advanced healthcare infrastructure, robust research, and significant adoption of Plasma Protease C1-inhibitor therapies for various rare diseases like hereditary angioedema.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Dosage form
    • 1.2.3. Distribution Channel
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Drug Class and Dosage Form Snapshot
  • 2.3. Distribution Channel Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Plasma Protease C1-inhibitor Market Variables, Trends, and Scope

  • 3.1. Plasma Protease C1-inhibitor Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Disease Awareness
      • 3.2.1.2. Advancements in Treatment Options
      • 3.2.1.3. Expansion of Indications
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High Cost of Treatment
      • 3.2.2.2. Side Effects and Safety Concerns
      • 3.2.2.3. Regulatory Challenges
  • 3.3. Plasma Protease C1-inhibitor Market Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTLE Analysis

Chapter 4. Plasma Protease C1-inhibitor Market Analysis, by Drug Class, 2018 - 2030 (USD Million)

  • 4.1. Drug Class Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Plasma Protease C1-inhibitor Market by Drug Class Outlook
    • 4.3.1. C1-inhibitors
      • 4.3.1.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.2. C1-esterase Inhibitor
      • 4.3.1.2.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.3. Recombinant Inhibitor
      • 4.3.1.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.2. Kallikrein Inhibitor
      • 4.3.2.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.3. Selective Bradykinin B2 Receptor Antagonist
      • 4.3.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Plasma Protease C1-inhibitor Market Analysis, by Dosage Form, 2018 - 2030 (USD Million)

  • 5.1. Dosage Form Market share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Plasma Protease C1-inhibitor Market by Dosage Form Outlook
    • 5.3.1. Lyphophlised
      • 5.3.1.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2. Injectables
      • 5.3.2.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Plasma Protease C1-inhibitor Market Analysis, by Distribution Channel, 2018 - 2030 (USD Million)

  • 6.1. Distribution Channel Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Plasma Protease C1-inhibitor Market by Distribution Channel Outlook
    • 6.3.1. Hospital Pharmacies
      • 6.3.1.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. Retail Pharmacies
      • 6.3.2.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. Online Pharmacies
      • 6.3.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Plasma Protease C1-inhibitor Market: Regional Estimates and Trend Analysis by Drug Class, by Dosage Form

  • 7.1. Plasma Protease C1-inhibitor Market: Regional Outlook
  • 7.2. North America
    • 7.2.1. North America Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. U.S. Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.2.2.3. Competitive/Market Scenario
      • 7.2.2.4. Regulatory Framework
      • 7.2.2.5. Reimbursement scenario
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Canada Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.2.3.3. Competitive/Market Scenario
      • 7.2.3.4. Regulatory Framework
      • 7.2.3.5. Reimbursement Scenario
    • 7.2.4. Mexico
      • 7.2.4.1. Key Country Dynamics
      • 7.2.4.2. Mexico Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.2.4.3. Competitive/Market Scenario
      • 7.2.4.4. Regulatory Framework
      • 7.2.4.5. Reimbursement Scenario
  • 7.3. Europe
    • 7.3.1. Europe Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. UK Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.2.3. Competitive/Market Scenario
      • 7.3.2.4. Regulatory Framework
      • 7.3.2.5. Reimbursement Scenario
    • 7.3.3. Germany
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Germany Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.3.3. Competitive/Market Scenario
      • 7.3.3.4. Regulatory Framework
      • 7.3.3.5. Reimbursement Scenario
    • 7.3.4. France
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. France Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.4.3. Competitive/Market Scenario
      • 7.3.4.4. Regulatory Framework
      • 7.3.4.5. Reimbursement Scenario
    • 7.3.5. Spain
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Spain Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.5.3. Competitive/Market Scenario
      • 7.3.5.4. Regulatory Framework
      • 7.3.5.5. Reimbursement Scenario
    • 7.3.6. Italy
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Italy Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.6.3. Competitive/Market Scenario
      • 7.3.6.4. Regulatory Framework
      • 7.3.6.5. Reimbursement Scenario
    • 7.3.7. Denmark
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Denmark Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.7.3. Competitive/Market Scenario
      • 7.3.7.4. Regulatory Framework
      • 7.3.7.5. Reimbursement Scenario
    • 7.3.8. Sweden
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Sweden Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.8.3. Competitive/Market Scenario
      • 7.3.8.4. Regulatory Framework
      • 7.3.8.5. Reimbursement Scenario
    • 7.3.9. Norway
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Norway Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.9.3. Competitive/Market Scenario
      • 7.3.9.4. Regulatory Framework
      • 7.3.9.5. Reimbursement Scenario
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Plasma Protease C1-inhibitor Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Japan Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.4.2.3. Competitive/Market Scenario
      • 7.4.2.4. Regulatory Framework
      • 7.4.2.5. Reimbursement Scenario
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. China Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.4.3.3. Competitive/Market Scenario
      • 7.4.3.4. Regulatory Framework
      • 7.4.3.5. Reimbursement Scenario
    • 7.4.4. India
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. India Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.4.4.3. Competitive/Market Scenario
      • 7.4.4.4. Regulatory Framework
      • 7.4.4.5. Reimbursement Scenario
    • 7.4.5. Australia
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Australia Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.4.5.3. Competitive/Market Scenario
      • 7.4.5.4. Regulatory Framework
      • 7.4.5.5. Reimbursement Scenario
    • 7.4.6. Thailand
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Thailand Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.4.6.3. Competitive/Market Scenario
      • 7.4.6.4. Regulatory Framework
      • 7.4.6.5. Reimbursement Scenario
    • 7.4.7. South Korea
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. South Korea Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.4.7.3. Competitive/Market Scenario
      • 7.4.7.4. Regulatory Framework
      • 7.4.7.5. Reimbursement Scenario
  • 7.5. Latin America
    • 7.5.1. Latin America Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Brazil Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.5.2.3. Competitive/Market Scenario
      • 7.5.2.4. Regulatory Framework
      • 7.5.2.5. Reimbursement Scenario
    • 7.5.3. Argentina
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Argentina Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.5.3.3. Competitive/Market Scenario
      • 7.5.3.4. Regulatory Framework
      • 7.5.3.5. Reimbursement Scenario
  • 7.6. MEA
    • 7.6.1. MEA Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. South Africa Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.6.2.3. Competitive/Market Scenario
      • 7.6.2.4. Regulatory Framework
      • 7.6.2.5. Reimbursement Scenario
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Saudi Arabia Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.6.3.3. Competitive/Market Scenario
      • 7.6.3.4. Regulatory Framework
      • 7.6.3.5. Reimbursement Scenario
    • 7.6.4. UAE
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. UAE Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.6.4.3. Competitive/Market Scenario
      • 7.6.4.4. Regulatory Framework
      • 7.6.4.5. Reimbursement Scenario
    • 7.6.5. Kuwait
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Kuwait Plasma Protease C1-inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.6.5.3. Competitive/Market Scenario
      • 7.6.5.4. Regulatory Framework
      • 7.6.5.5. Reimbursement Scenario

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Key Company Profiles
    • 8.2.1. CSL
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Product benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. Takeda Pharmaceutical Company Limited
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Product benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. Pharming
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. KalVista Pharmaceuticals.
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Sanquin
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. BioCryst Pharmaceuticals, Inc.
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. CENTOGENE N.V.
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global protease C1-inhibitor market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global plasma protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 5 Global plasma protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 6 Global plasma protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7 North America protease C1-inhibitor market, by country, 2018 - 2030 (USD Million)
  • Table 8 North America protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 9 North America protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 10 North America protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11 U.S. protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 12 U.S. protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 13 U.S. protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 14 Canada protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 15 Canada protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 16 Canada protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 17 Mexico protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 18 Mexico protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 19 Mexico protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Europe protease C1-inhibitor market, by country, 2018 - 2030 (USD Million)
  • Table 21 Europe protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 22 Europe protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 23 Europe protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24 Germany protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 25 Germany protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 26 Germany protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 27 UK protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 28 UK protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 29 UK protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30 France protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 31 France protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 32 France protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33 Italy protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 34 Italy protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 35 Italy protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 36 Spain protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 37 Spain protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 38 Spain protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 39 Denmark protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 40 Denmark protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 41 Denmark protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 42 Sweden protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 43 Sweden protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 44 Sweden protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45 Norway protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 46 Norway protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 47 Norway protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific protease C1-inhibitor market, by country, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 52 China protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 53 China protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 54 China protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 55 Japan protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 56 Japan protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 57 Japan protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 58 India protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 59 India protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 60 India protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61 South Korea protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 62 South Korea protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 63 South Korea protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 64 Australia protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 65 Australia protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 66 Australia protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 67 Thailand protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 68 Thailand protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 69 Thailand protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 70 Latin America protease C1-inhibitor market, by country, 2018 - 2030 (USD Million)
  • Table 71 Latin America protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 72 Latin America protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 73 Latin America protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74 Brazil protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 75 Brazil protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 76 Brazil protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 77 Argentina protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 78 Argentina protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 79 Argentina protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 80 MEA protease C1-inhibitor market, by country, 2018 - 2030 (USD Million)
  • Table 81 MEA protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 82 MEA protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 83 MEA protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 84 South Africa protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 85 South Africa protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 86 South Africa protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 90 UAE protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 91 UAE protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 92 UAE protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 93 Kuwait protease C1-inhibitor market, by drug class, 2018 - 2030 (USD Million)
  • Table 94 Kuwait protease C1-inhibitor market, by dosage form, 2018 - 2030 (USD Million)
  • Table 95 Kuwait protease C1-inhibitor market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Plasma protease C1-inhibitor market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Drug class and dosage form segment snapshot
  • Fig. 11 Distribution channel segment snapshot
  • Fig. 12 Competitive landscape snapshot
  • Fig. 13 Global Pharmaceutical Market, (USD billion)
  • Fig. 14 Market dynamics
  • Fig. 15 Porter's five forces analysis
  • Fig. 16 PESTLE analysis
  • Fig. 17 Plasma protease C1-inhibitor: Drug Class outlook and key takeaways
  • Fig. 18 Plasma protease C1-inhibitor market: Drug Class market movement analysis
  • Fig. 19 C1-inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 C1-esterase Inhibitor market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Recombinant Inhibitor market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Kallikrein Inhibitor market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Selective Bradykinin B2 Receptor Antagonist market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Plasma protease C1-inhibitor: Dosage form outlook and key takeaways
  • Fig. 25 Plasma protease C1-inhibitor market: Dosage form market movement analysis
  • Fig. 26 Lyphophlised market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Injectables market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Plasma protease C1-inhibitor: Distribution channel outlook and key takeaways
  • Fig. 29 Plasma protease C1-inhibitor market Distribution channel market movement analysis
  • Fig. 30 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Retail Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Online Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Plasma protease C1-inhibitor market revenue, by region, 2023 & 2030 (USD Million)
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 Regional marketplace: Key takeaways
  • Fig. 36 North America plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Key country dynamics
  • Fig. 38 US plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Key country dynamics
  • Fig. 40 Canada plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Key country dynamics
  • Fig. 42 Mexico plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Europe plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 UK plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Key country dynamics
  • Fig. 47 Germany plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 France plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 Spain plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Key country dynamics
  • Fig. 53 Italy plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Key country dynamics
  • Fig. 55 Denmark plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Key country dynamics
  • Fig. 57 Sweden plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 Norway plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Rest of Europe plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Asia Pacific plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Key country dynamics
  • Fig. 63 Japan plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 China plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 China regulatory details
  • Fig. 67 India plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 Australia plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Thailand plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 South Korea plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 South Korea reimbursement scenario
  • Fig. 75 Rest of Asia Pacific plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Latin America plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Brazil plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Brazil regulation details
  • Fig. 80 Brazil reimbursement scenario
  • Fig. 81 Key country dynamics
  • Fig. 82 Argentina plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Argentina regulatory framework
  • Fig. 84 Rest of Latin America plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Key country dynamics
  • Fig. 86 South Africa plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Key country dynamics
  • Fig. 88 Saudi Arabia plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Key country dynamics
  • Fig. 90 UAE plasma protease C1-inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Key country dynamics
  • Fig. 92 Kuwait plasma protease C1-inhibitor market estimates and forecasts, 2018
  • Fig. 93 Rest of MEA plasma protease C1-inhibitor market estimates and forecasts,
  • Fig. 94 Company/competition categorization
  • Fig. 95 Company market share analysis, 2023
  • Fig. 96 Strategy mapping